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Church AC, Martin DH, Wadsworth R, Bryson G, Fisher AJ,
Welsh DJ, Peacock AJ. The reversal of pulmonary vascular remod-
eling through inhibition of p38 MAPK-alpha: a potential novel anti-
inflammatory strategy in pulmonary hypertension. Am J Physiol Lung
Cell Mol Physiol 309: L333–L347, 2015. First published May 29,
2015; doi:10.1152/ajplung.00038.2015.—The p38 mitogen-activated
protein kinase (MAPK) system is increasingly recognized as an
important inflammatory pathway in systemic vascular disease but its
role in pulmonary vascular disease is unclear. Previous in vitro studies
suggest p38 MAPK is critical in the proliferation of pulmonary
artery fibroblasts, an important step in the pathogenesis of pulmonary
vascular remodeling (PVremod). In this study the role of the p38
MAPK pathway was investigated in both in vitro and in vivo models
of pulmonary hypertension and human disease. Pharmacological in-
hibition of p38 MAPK in both chronic hypoxic and monocrotaline
rodent models of pulmonary hypertension prevented and reversed the
pulmonary hypertensive phenotype. Furthermore, with the use of a
novel and clinically available p38 MAPK antagonist, reversal of
pulmonary hypertension was obtained in both experimental models.
Increased expression of phosphorylated p38 MAPK and p38 MAPK
was observed in the pulmonary vasculature from patients with idio-
pathic pulmonary arterial hypertension, suggesting a role for activa-
tion of this pathway in the PVremod A reduction of IL-6 levels in
serum and lung tissue was found in the drug-treated animals, suggest-
ing a potential mechanism for this reversal in PVremod. This study
suggests that the p38 MAPK and the -isoform plays a pathogenic
role in both human disease and rodent models of pulmonary hyper-
tension potentially mediated through IL-6. Selective inhibition of this
pathway may provide a novel therapeutic approach that targets both
remodeling and inflammatory pathways in pulmonary vascular dis-
ease.
pulmonary hypertension; p38 MAPK
PULMONARY HYPERTENSION continues to be a cause of significant
morbidity and mortality and there remains a need for novel
approaches in tackling the underlying pulmonary vascular
remodeling (PVremod). This remodeling is characterized by
increased proliferation of vascular cells, increased extracellular
matrix and collagen deposition, recruitment of bone marrow-
derived cells to the vascular wall, and increased inflammatory
responses (4). Although inflammation in driving this process is
now recognized, with, for example, interleukin-6 (IL-6) being
shown to have an important pathogenic role, the exact link
between inflammation and pulmonary vascular remodeling
remains unclear (2, 15).
Although both smooth muscle and endothelial cells are vital
to the pathology of pulmonary hypertension, the fibroblast
plays a critical role in PVremod by undergoing proliferation in
response to many stimuli, for example, hypoxia, and driving
smooth muscle proliferation (13). In addition, it has been
established by our own group and others that the adventitial
fibroblast can contribute significantly to inflammatory pro-
cesses and is a source of cytokines and chemokines, which can
recruit key inflammatory cells such as monocytes/macrophages
to the sites of PVremod (7, 17, 20). Previous work from our
group has demonstrated in vitro that activation of the p38
mitogen-activated protein kinase (MAPK) pathway is essential
to fibroblast proliferation in the hypoxic model and that its
inhibition can block the hypoxic proliferative response (11,
21). In addition, p38 MAPK is well established in other
inflammatory pathological states as being a key intermediary
pathway and plays an important role in mediating cellular
responses to proinflammatory cytokines. Phosphorylation and
activation of the alpha ()-isoform of p38 MAPK have been
implicated in both driving the hypoxic proliferation of the
adventitial fibroblast (9) and release of mitogens from the
fibroblast that stimulate adjacent smooth muscle cell prolifer-
ation and recruit proinflammatory cells (13, 21). Fibroblast
proliferation is an important mechanism underpinning PVre-
mod and at least in hypoxia is p38 MAPK dependent (14). This
contrasts with the systemic vascular fibroblast, which does not
proliferate nor does it upregulate the p38 MAPK pathway in
hypoxia, offering the possibility of selectively targeting the
abnormal pulmonary vascular tree in pulmonary hypertension
with minimal effect on systemic vessels (12). In addition p38
MAPK has been implicated in the development of pulmonary
hypertension in other animal models, although no clear mech-
anism has been suggested. Although both inflammation and
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p38 MAPK have been implicated in PVremod a possible link
between the two in pulmonary hypertension has not previously
been suggested. This study sought to investigate the hypothesis
that p38 MAPK, and the -isoform in particular, mediates
PVremod and pulmonary hypertension through an inflamma-
tory process by employing both prevention and reversal inhib-
itor strategies in vivo and exploring p38 MAPK expression in
human disease.
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METHODS
Primary Cell Culture
Fibroblasts from adult male Sprague-Dawley rats were obtained
from freshly excised vessels using a modified explant technique, as
previously described (10). Briefly, vessels were dissected free and
opened into a flat sheet and muscular tissue and endothelial cell layers
were removed by gentle abrasion. The remaining tissue (adventitia)
was then dissected into 1-mm3 portions, 25 of which were evenly
distributed over the base of a 25-cm2 culture flask containing 2 ml of
DMEM with 20% fetal calf serum (FCS), penicillin/streptomycin (400
IU/ml and 400 mg/ml), amphotericin B (5 mg/ml), and L-glutamine
(27 mg/ml). Explants were incubated in a humidified atmosphere of
5% CO2 in air at 37.0°C. Although there are no specific fibroblast
markers, we have previously shown using cell morphology and the
absence of smooth muscle actin that this technique produces a pure
culture of fibroblasts (21). To further characterize the cell population,
vimentin staining was also used. Cells were subsequently maintained
in DMEM containing 10% FCS, supplemented with antibiotics and
L-glutamine as before, and used between passage 3 and 10. All
chemicals were obtained from Invitrogen (Paisley) unless otherwise
stated.
Growth of Cells in a Hypoxic Environment
Maintenance of cells in a nitrogen-supplemented, humidified, tem-
perature-controlled incubator (Galaxy R; Wolf Laboratories, York,
UK) allowed control of internal chamber oxygen levels at 5%, while
CO2 level was maintained at 5%. This achieved a tissue culture
supernatant PO2 of 35 mmHg for the hypoxic conditions (10).
Animal Models
Adult male Sprague-Dawley rats, weighing 200–250 g, were used
in all experiments. All experiments were approved by the University
of Strathclyde Ethics Committee and were performed under authori-
zation of the Animals (Scientific procedures) Act 1986.
Chronic hypoxic model. Animals were maintained in a hypobaric
chamber at ambient pressure of 550 mmHg for up to 4 wk, equivalent
to an oxygen concentration of 10%. The chamber was depressurized
initially over 2 days. To allow daily injections the chamber was
brought back to atmospheric pressure over a 1-h period and injections
performed and then the chamber was depressurized again with gradual
reductions over 1 h. The chamber was unsealed for a maximum of 30
min/day. Age and weight matched normoxic animals were housed in
an adjacent perspex container but without depressurization. Animals
received food and water ad libitum. Animals body weights were
measured twice weekly.
Monocrotaline model. Monocrotaline (MCT) was dissolved in 1 M
HCl and then neutralized with a similar volume of 1 M sodium
hydroxide. Animals were then injected with 60 mg/kg MCT subcu-
taneously in the scruff of the neck. Control animals received a similar
volume of saline injected subcutaneously. The animals body weights
were measured three times a week. The agents used were SB203580
and PH-797804. Both are p38 MAPK -specific but the PH-797804
has been shown to be more specific and tolerated in humans.
The animal groups were divided up into: 1) a prevention study for
chronic hypoxia where the p38 MAPK antagonists were administered
at the start of the animals being exposed to the hypobaric chamber; 2)
a reversal study for chronic hypoxia where the animals were allowed
to develop pulmonary hypertension for 2 wk and were then treated
with SB203580, a p38 MAPK antagonist; 3) a reversal study for the
MCT-treated animals with the p38 MAPK antagonist SB203580 as
above; 4) a reversal study with the p38 MAPK antagonist PH-797804
for the chronic hypoxic animals; and 5) a reversal study with the p38
MAPK antagonist PH-797804 for the MCT animals.
Measurement of Hemodynamics and Right Ventricular Hypertrophy
Rats were anesthetized using subcutaneous administration of a
50:50 mixture of midazolam (Hypnovel) and fentanyl/flunisone (Hyp-
norm) at a dose of 0.15 ml per 100 g body wt. The animals underwent
tracheotomy and were established on a ventilator. Then a midline
thoracotomy was performed and the heart was exposed. The right
ventricular (RV) pressure was obtained by advancing a 21-G needle
attached to a pressure transducer into the RV. The pressures were
recorded using a Powerlab data acquisition system (AD Instruments)
and analyzed using LabChart software. Placement of the catheter in
the RV was established by direct visualization and afterwards by
postmortem examination. The tracings were allowed to stabilize for 3
min.
Fig. 1. Proproliferative fibroblast phenotype and paracrine smooth muscle proliferation mediated by p38 MAPK in fibroblasts from experimental models of
pulmonary hypertension (PH). A: cells were isolated from the 2nd order division of the pulmonary artery and grown in normoxic culture. The effect of serum
stimulation was observed on these cells. At baseline with no serum stimulation, the chronic hypoxic (CH) and monocrotaline (MCT) pulmonary artery fibroblast
(PAF) had an increased proliferative rate compared with the PAF derived from normoxic wild-type rats. This was also seen with low dose 1% serum stimulation.
The effect was lost at 5% serum stimulation, which may reflect cell contact inhibition. The thymidine incorporation assay was used to assess the proliferation
of the cells, and the results presented are representative of 3 experiments with triplicate values in each experiment. Values are means  SE. ***P  0.001. B:
this immunoblot shows that under normoxic conditions the PAFs derived from both CH and MCT animals show a constitutive activation of p38 MAPK with
increased levels of p-p38 detected. Cells were from passage 3 and were quiescesed in serum free medium for 24 h before harvest. Immunoblot for phospho-p38
and total p38 MAPK was performed and representative of 3 experiments. C: PAFs derived from MCT animals were isolated and then quiescesed for 24 h in
serum free media. After 24 h, cells were stimulated with either 1% serum or some remained in serum free media SB203580 (p38 inhib). The conditioned media
were aspirated from the wells after 24 h and passed through a cell sieve to give conditioned media from serum free cells  SB203580 (SF cond med, SF cond
med  p38 inhib) and 1% stimulated cells  SB203580 (1% cond med, 1% cond med  p38 inhib). The conditioned media were added to smooth muscle cells
for 48 h before a proliferation assay was performed. Both SF cond med and 1% cond med resulted in increased proliferation of pulmonary artery smooth muscle
cells (PASMCs) while this effect was lost in the conditioned media from the PAFs, which had been coincubated with SB203580. There was no effect of
SB203580 directly on the PASMCs. Values are means  SE. Data shown from 3 experiments. **P  0.005. D: PAFs derived from CH animals were isolated
and then quiescesed for 24 h in serum free media. After 24 h, cells were stimulated with either 1% serum or some remained in serum free media  SB203580
(p38 inhib). The conditioned media were aspirated from the wells after 24 h and passed through a cell sieve to give conditioned media from serum free cells SB203580
(SF cond med, SF cond med  p38 inhib) and 1% stimulated cells  SB203580 (1% cond med, 1% cond med  p38 inhib). The conditioned media were added
to normal PASMCs for 48 h before a proliferation assay was performed. Both SF cond med and 1% cond med resulted in increased proliferation of PASMCs
while this effect was lost in the conditioned media from the PAF, which had been coincubated with SB203580. There was no effect of SB203580 directly on the
PASMCs. Values are means  SE. Data shown from 3 experiments. *P  0.05; **P  0.005. E: PAF from normal animals were exposed to 48 h normoxia or
hypoxia  SB203580. The supernatant was collected and analyzed using cytokine array. The above are representative of triplicate samples from 3 different
animals. Exposure times for each blot was the same. The results for IL-6 are shown and are presented as a relative density plot vs. the positive control blots.
***P  0.005. F: PASMCs are quiescesed and then incubated with conditioned media derived from normoxic or hypoxic PAF. The hypoxic conditioned media
induced PASMC proliferation. When both the conditioned media and anti-IL-6 were added to the PASMCs, there was an inhibition in the proliferative stimulus.
Results are means  SE from 3 replicates from 3 different animals. ***P  0.001.
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Systemic blood pressure. This was measured by noninvasive tail-
cuff methods as previously outlined (26).
Assessment of right ventricular hypertrophy. The RV was separated
from the left ventricle (LV) and septum (S) using a dissecting
microscope. The ventricles were blotted and then weighed. The
degree of RV hypertrophy (RVH) was determined by the ratio of the
weight of the RV to the LV  S.
Thymidine proliferation assay. Rat pulmonary artery fibroblasts
(RPAFs) were grown in normoxic conditions to 60% confluency in
24-well plates and then quiesced for 24 h in serum free medium. Cells
were then cultured under conditions of normoxia or hypoxia, in the
presence or absence of serum and experimental mediators, for a
further 24 h. Increased proliferation of RPAFs to hypoxia is seen with
concentrations of serum 0.1%–10%. For these experiments, 1% serum
was selected as this maximizes differences between normoxic and
hypoxic proliferation.
Fibroblasts were pulsed with [3H]thymidine (0.1 Ci/well) 4 h
before the end of the 24 h experimental period with scintillation
counting as previously described. To assess proliferation and viability
24 h, experiments were repeated, and fibroblasts were removed from
the wells by 0.05% trypsin and then counted using a Fischer hemo-
cytometer/0.4% trypan blue.
Immunoblotting. Frozen lung tissue was homogenized on ice using
a rotor blender (Fisher) on ice in Tissue protein extraction reagent
(T-Per from Sigma). This was supplemented with phosphatase and
protease inhibitors (Halt; Sigma). Homogenates were then centrifuged
for 15 min at 4°C, and the supernatants were collected and frozen at
80°C until required. The protein concentration was established
using a BCA technique (Thermo Scientific), and 30–40 g of protein
were then separated by electrophoresis on a Bis-Tris NuPage gel.
Proteins were then transferred to PVDF Immobilon and transfer was
confirmed with Ponceau red stain. The blot was blocked at room
temperature for 1–2 h in 5% nonfat milk in Tris-buffered saline
containing 0.05% Tween-20. Membranes were then incubated over-
night at 4°C with primary antibody diluted accordingly in 5% milk/
TBS-T. These were subsequently washed using TBS-T and then
incubated with secondary antibody for 1–2 h at room temperature. The
antibody labeling was visualized using enhanced chemiluminscence
(ECL; Amersham) with exposure to autoradiographic film (GE
Healthcare).
Antibodies and drugs. Antibodies used for the immunoblotting and
immunohistochemistry were phospho-p38 MAPK (Cell Signaling),
p38 MAPK, p38 MAPK	, total p38 MAPK (Cell Signaling), phos-
Fig. 2. Increased expression of p38 MAPK -iso-
form in animal models of PH. A: lungs from normal,
CH, and MCT animals were harvested and homog-
enized with a cocktail of phosphatase and kinase
inhibitors. The protein concentration was quantified
using the BCA method. Equal concentrations were
then loaded on a gel and blotted for p38 MAPK
and 
-actin for loading control. There are 3 wells for
each condition. Immunoblot shown is best represen-
tative of 3 experiments using 3 different animals
with each condition. B: densitometry of immunoblot
in A. Values are mean arbitrary values from 3
immunoblots expressed relative to the value for

-actin. *P  0.05 by ANOVA. C: lung sections (5
mm) were prepared from normal, CH, and MCT
animals. Sections were stained for p38 MAPK
using 1:400 dilution. Magnification: 20. Bar rep-
resents  150 mm. Arrows identify blood vessels.
D: lungs from normal, CH, and MCT animals were
harvested and homogenized with a cocktail of phos-
phatase and kinase inhibitors. The protein concen-
tration was quantified using BCA method. Equal
concentrations were then used in a p38 MAPK
activity assay using immunoprecipitation and the
phosphorylation of activating transcription factor-2
(ATF-2) as a read out. Immunoblot shown is repre-
sentative of 3 experiments using 3 different animals.
E and F: lungs from normal, CH, and MCT animals
were harvested and homogenized with a cocktail of
phosphatase and kinase inhibitors. The protein con-
centration was quantified using BCA method. Equal
concentrations were then loaded on a gel and blotted
for phosphorylated p38 MAPK and 
-actin for load-
ing control. Immunoblot shown is representative of
3 experiments using 3 different animals with each
condition. Densitometry is shown for remaining
blots. *P  0.05.
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pho- and total ATF-2 (Cell Signaling), 
-actin (Abcam), phospho-
STAT3, total STAT3, and -smooth muscle actin (Dako).
The p38 MAPK antagonist SB203580 was obtained from Selleck
Chemicals and the dose used was 20 mg/kg given intraperitoneally
once daily. The p38 MAPK antagonist PHA-00797804 was used with
permission from Pfizer. This was administered intraperitoneally at 3
mg/kg once daily. The difference in kinase activity and specificity
between SB203580 and PH-797804 is as follows: SB203580 IC50: 50
nM, Ki: 21 nM vs. PH-797804 IC50: 26 nM, Ki: 3.9 nM.
Quantification of pulmonary vascular remodeling. Pulmonary vas-
cular remodeling was quantified by determining the degree of mus-
cularization present in smaller pulmonary arterial vessels with a
diameter 80 m. Standard immunohistochemical techniques were
used as described below with staining for -smooth muscle actin. In
each lung section, pulmonary arteries were characterized as com-
pletely muscularized (with complete occlusion or slit-like appearance
of lumen), partially muscularized (with incomplete rings of smooth
muscle), or nonmuscularized (with no smooth muscle present). The
Fig. 3. PH is prevented by administration of
SB203580, a p38 MAPK inhibitor. A and
B: animals were exposed to a hypobaric
hypoxic environment for 2 wk. Some ani-
mals received daily injections of SB203580.
Hemodynamics (A) and hematocrit (B) were
measured after 2 wk. RVSP, right ventricu-
lar (RV) systolic pressure. Data represent
mean values  SE. Total animals n  5–6
per group. C: hearts were isolated from the
animals and the RV was dissected out from
the left ventricle (LV) and septum. The ven-
tricles were dry blotted and then weighed,
and the ratio was calculated. The total RV
weight was also plotted. Values are means
SD; n  5 per group. **P  0.05. D:
noninvasive systemic blood pressure taken
by tail-cuff measurement. E and F: rats were
exposed to hypoxia  SB203580. The lungs
were removed after experiment and sections
(5 mm) cut. These were stained with
-smooth muscle actin and the vessels 80
mm were analyzed for degree of muscular-
ization. Five random fields per slide were
analyzed with 3 slides per animal. The ves-
sels were categorized as completely, par-
tially, or nonmuscularized and are presented
as numbers per total number of vessels pres-
ent in each field. Groups analyzed by
ANOVA for overall change with posttest
analysis; n  5 animals. ***P  0.001, for
A–C and E.
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number of vessels in each category was determined by counting the
total number in five random fields per slide and using three slides per
animal. The vessels were then categorized by degree of musculariza-
tion. The individual assessor was blinded to the slides.
Immunohistochemistry. IN VIVO MODELS. Immediately after exper-
imentation, the left lung was removed and perfusion fixed with 10%
neutral buffered formalin. Following fixation the paraffin embedded
lungs were sectioned for analysis. These sections were immunohisto-
chemically stained for p38 MAPK or -smooth muscle actin using
standard techniques.
HUMAN TISSUE. Lung tissue from two female patients with idio-
pathic pulmonary arterial hypertension (IPAH) was obtained at the
time of lung transplantation centre with local ethics approval REC
Reference 11/NE/0291. These patients were in New York Heart
Association Functional Class 4 and on optimal background therapy
including parenteral prostanoid therapy. Material was fixed in 10%
phosphate-buffered formalin by airway perfusion before being pre-
pared for sectioning. Samples were selected from specimens that
showed excellent tissue preservation. Control adult lung was obtained
from patients who were undergoing routine cardiothoracic interven-
tion, with no echocardiographical evidence of pulmonary hyperten-
sion. Sections were immunohistochemically stained for p38 MAPK
and phospho-p38 MAPK. Control tissue was obtained from patients
undergoing lung resection for solitary lung nodules and had no
evidence of pulmonary hypertension on echocardiography.
Enzyme-linked immunosorbent assay/cytokine array. An IL-6 en-
zyme-linked immunosorbent assay (ELISA; R&D Systems) was used
to analyze lung homogenates prepared as previously described. The
protocol as per manufacturer’s instructions was followed. The rat
proteome profiler (R&D Systems) was used to analyze 29 cytokines/
chemokines as per manufacturers instructions. This is a qualitative
analysis rather than quantitative.
SYBR green quantitative PCR. Gene expression of the pulmonary
artery fibroblasts was analyzed using SYBR green quantitative PCR.
RNA was isolated from the cells using RNAEasy purification kits
(Invitrogen), and the purity was quantified using Nanodrop reader.
Then these were reverse transcribed and real-time quantitative PCR
performed using SYBR Green PCR Mastermix and primers for rat
IL-6 (Integrated DNA Technologies) on Applied Biosystems
ABI7500 PCR machine. These experiments were done in triplicate.
Relative gene expression was quantified by comparison of the “Ct”
method relative to 
-actin as a housekeeping gene.
Data analysis. For normally distributed values, responses were
reported as means  SE and Students t-test was used. The n value
refers to the number of animals involved per experimental procedure.
For multiple comparisons of means across different experimental
groups, ANOVA was performed with Bonferonni post hoc analysis.
Values of P  0.05 were accepted as statistically significant.
RESULTS
p38 MAPK and the -Isoform Is Important in Both In Vitro
And In Vivo Experimental Models of Pulmonary Vascular
Remodeling
In vitro: hypoxia. Our group and others have shown previ-
ously that fibroblasts isolated from chronic hypoxic animals
have undergone a phenotypic switch, which results in consti-
tutive activation of p38 MAPK and a proproliferative pheno-
type. Whether this effect is seen in other models of pulmonary
hypertension is unknown. Therefore, we examined the prolif-
erative potential of fibroblasts derived from MCT animals and
compared them to that of fibroblasts isolated from both normal
and chronic hypoxic animals (Fig. 1A). This clearly showed an
increased predisposition to proliferation by the MCT-derived
fibroblasts in relation to low dose serum stimulation. The effect
was lost at 5% serum stimulation, which may reflect cell
contact inhibition.
We confirmed that there was increased phosphorylation of
p38 MAPK in both chronic hypoxic and MCT fibroblasts
compared with normal fibroblasts (Fig. 1B), suggesting up-
regulation of this pathway in those fibroblasts derived from
experimental models of pulmonary hypertension. This was
confirmed on densitometry (data not shown).
The addition of conditioned media isolated from chronic
hypoxic and MCT fibroblasts to smooth muscle cells resulted
in increased proliferation (Fig. 1, C and D). This effect could
be prevented when the fibroblasts were incubated with a p38
MAPK inhibitor before collection of the conditioned media. In
contrast p38 MAPK inhibition had no direct effect on pulmo-
nary artery smooth muscle cell (PASMC) proliferation. This
suggests that various mitogens are released from the fibroblast
in a p38 MAPK-dependent mechanism, which can promote
pulmonary vascular remodeling, and that this is conserved in
fibroblasts derived from experimental models of pulmonary
hypertension. To investigate this further a cytokine screening
array was used (data not shown). Various cytokines were
Fig. 4. PH in 2 in vivo animal models is reversed by the administration of SB203580, a p38 MAPK inhibitor. A: animals were exposed to a hypobaric hypoxic
environment for 2 wk and then p38 MAPK inhibition was commenced. Hemodynamics and RVSP were measured after 4 wk. Data represent mean values 
SE. Total animals n  5–6 per group. **P  0.01; ***P  0.001, for normal relative to all other conditions. B: hearts were isolated form the animals and the
RV dissected out from the LV and septum. The ventricles were dry blotted and then weighed, and the ratio was calculated. Values are means  SE; n  6–7.
**P  0.01; ***P  0.005. C: hematocrit ratio. D: the lungs were removed after experiment and sections (5 mm) cut. These were stained for -smooth muscle
actin and the vessels 80 mm were analyzed for degree of muscularization. Five to 10 random fields were analyzed with 3 slides per animal. The vessels were
categorized as completely, partially, or nonmuscularized. Groups analyzed by ANOVA for overall change with posttest analysis; n  6 animals. **P  0.01;
***P  0.001. E: the lungs were removed after experiment and sections (5 mm) cut. These were stained for -smooth muscle actin and the vessels 100 mm
were analyzed for degree of muscularization. Five to 10 random fields (40) were analyzed with 3 slides per animal. The vessels were categorized as
muscularized or nonmuscularized and the percentage of muscularized vessels calculated. Groups were analyzed by ANOVA for overall change with posttest
analysis; n  7 animals. ****P  0.0001; P  0.05 for hypoxic drug-treated vs. day 14 hypoxic control. **P  0.01; ***P  0.001. F and G: animals were
injected with MCT and after 2 wk p38 MAPK inhibition was commenced with daily injections. Hemodynamics and RVH were measured after 4 wk. Data
represent mean values  SE. Total animals n  6–7 per group. *P  0.05; ***P  0.001, for F. *P  0.05; **P  0.01, for G. H: the lungs were removed
after experiment and sections (5 mm) cut. These were stained for -smooth muscle actin, and the vessels 80 mm were analyzed for degree of muscularization.
Five to 10 random fields (40) were analyzed with 3 slides per animal. The vessels were categorized as completely, partially or nonmuscularized. Groups were
analyzed by ANOVA for overall change with posttest analysis; n  6 animals. *P  0.05; ***P  0.001. I: lungs were removed after experiment and sections
(5 mm) cut. These were stained for -smooth muscle actin, and the vessels 100 mm were analyzed for degree of muscularization. Five to 10 random fields
(40) were analyzed with 3 slides per animal. The vessels were categorized as muscularized or nonmuscularized, and the percentage of muscularized vessels
was calculated. Groups were analyzed by ANOVA for overall change with posttest analysis; n 6 animals. ****P 0.0001; P 0.05 for hypoxic drug-treated
vs. day 14 MCT control.
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identified as being released into the supernatant from hypoxic
fibroblasts and perhaps one of the most important with rele-
vance to PVremod is IL-6. Other cytokines/chemokines iden-
tified were VEGF-A, CXCL-1, CXCL3, TIMP-1, LIX, and
MIP-3.
With the addition of p38 MAPK inhibitor SB203580, the
proinflammatory profile was returned to that of normoxic
fibroblasts, suggesting a key role of p38 MAPK in release of
proinflammatory mediators. The importance of IL-6 in the
conditioned media were demonstrated by abrogation of the
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proliferative effect when the conditioned media were added in
the presence of anti-IL-6 antibody (Fig. 1F). Although we
identified other chemokines and cytokines, the significance of
IL-6 in pulmonary vascular biology has already been shown
and therefore seemed an appropriate signal to focus on.
In vivo: chronic hypoxia and MCT models. Expression of
p38 MAPK was increased in both chronic hypoxic and MCT
rat models of pulmonary hypertension after 2 wk (Fig. 2, A
and B).
Immunohistochemistry showed increased p38 MAPK in
the small pulmonary vessels of both chronic hypoxic and MCT
animals. This staining was distributed throughout the vessel
wall with notable staining in the adventitial and endothelial
compartments (Fig. 2C). With the use of a p38 MAPK activity
assay, increased activity was demonstrated in whole lung
homogenates from chronic hypoxic and MCT animals (Fig.
2D) suggesting because of increased expression there was also
increased activity of the p38 MAPK pathway. Furthermore,
increased phosphorylated total p38 MAPK was observed in the
lungs of those animals with pulmonary hypertension (Fig. 2, E
and F). We did not find changes in expression of 
- or 	p38
MAPK isoforms (data not shown).
Administration of the p38 MAPK Inhibitor SB203580 the
Development of Chronic Hypoxic-Induced Pulmonary
Hypertension
We administered daily p38 MAPK-specific pharmacolog-
ical inhibitor (SB203580) or vehicle (DMSO) via intraperito-
neal injections to animals maintained in a hypoxic environ-
ment. After 14 days RV systolic pressure (RVSP) and RVH
were significantly increased (P  0.005) in the vehicle-treated
animals but remained normal in the animals with the p38
MAPK inhibitor (Fig. 3, A–D).
There was a significant increase in the percentage of fully
muscularized vessels in the vehicle group compared with the
normal animals. This increase was significantly less in the
drug-treated group indicating prevention of PVremod (Fig. 3, E
and F). Knockdown of p38 MAPK activity in the lungs was
confirmed by looking at ATF-2 phosphorylation (data not
shown).
The p38 MAPK Inhibitor SB203580 Reversed Chronic
Hypoxic and MCT-Induced Pulmonary Hypertension
Chronic hypoxic pulmonary hypertension. Animals were
exposed to hypoxia for a period of 2 wk and then treated with
daily intraperitoneal injections of SB203580 or vehicle for a
further 2 wk while remaining in hypoxia. There was a signif-
icant reduction in the RVSP in the drug-treated group com-
pared with the vehicle-treated group at 4 wk and control
hypoxic animals after 2 wk (Fig. 4A), with almost full reversal
to that of normal animals.
The degree of RVH was reversed significantly (by 29%) in
the drug-treated animals (Fig. 4B). The degree of PVremod
was also reduced in the drug-treated animals compared with
the control untreated animals (Fig. 4, C and D). The systemic
blood pressure (BP) was unchanged between groups although
the BP was lower in the 28-day hypoxic group (data not
shown).
MCT-induced pulmonary hypertension. Two weeks after an
injection of MCT, there was an elevated RVSP and increased
RVH consistent with the development of pulmonary hyperten-
sion in this group of animals. (Fig. 4, E and F). There was no
difference between the RVSP rise seen in MCT control animals
at 14 or 28 days.
After 14 days, these animals were injected daily with vehicle
or SB203580 for a further 2 wk. This led to a significant
reduction in the RVSP compared with both the 14- and the
28-day time points in MCT controls (Fig. 4E). There was a
significant improvement in the degree of RVH observed in the
drug-treated animals which almost returned to normal (Fig.
4F). This was mirrored by a reduction in the degree of
muscularization in the small vessels in the drug-treated animals
(Fig. 4, G and H). There was no difference in the systemic BP
between the MCT groups (data not shown).
Reversal of Chronic Hypoxic and MCT-Induced Pulmonary
Hypertension with a Novel p38 MAPK-Selective Inhibitor
(PH-797804)
To examine the hypothesis that the -isoform is important
in the pulmonary hypertensive phenotype, we utilized a
Fig. 5. PH in a reversal strategy in 2 in vivo animal models by administration of PH-797804, a more selective p38 MAPK inhibitor. A and B: animals were
exposed to CH and after 2 wk p38 MAPK inhibition was commenced with daily injections. Hemodynamics and RV hypertrophy (RVH) were measured after
4 wk. Data represent mean values SE. *P 0.05; **P 0.01 for A. **P 0.01; ***P 0.001, for B. C: the lungs were removed after experiment and sections
(5 mm) were cut. These were stained with -smooth muscle actin and the vessels80 mm were analyzed for degree of muscularization. Five to 10 random fields
(40) were analyzed with 3 slides per animal. The vessels were categorized as completely, partially, or nonmuscularized. Groups analyzed by ANOVA for
overall change with posttest analysis; n  10 animals. **P  0.01; P  0.05 for complete muscularized group in drug-treated vs. day 14 hypoxic control. D:
lungs were removed after experiment and sections (5 mm) cut. These were stained with -smooth muscle actin and the vessels 100 mm were analyzed for
degree of muscularization. Five to 10 random fields (40) were analyzed with 3 slides per animal. The vessels were categorized as muscularized or
nonmuscularized and the percentage of muscularized vessels calculated. Groups analyzed by ANOVA for overall change with posttest analysis; n  10 animals.
****P 0.0001; P 0.05 for hypoxic drug-treated vs. day 14 hypoxic control. E and F: animals were injected with MCT and after 2 wk p38 MAPK inhibition
was commenced with daily injections. Hemodynamics and RVH were measured after 4 wk. Data represent mean values  SE. Total animals n  14–15 per
group. ***P 0.001 for E. *P 0.05; **P 0.01 for F. G: the lungs were removed after experiment and sections (5 mm) cut. These were stained with -smooth
muscle actin and the vessels 80 mm were analyzed for degree of muscularization. Five to 10 random fields (40) were analyzed with 3 slides per animal. The
vessels were categorized as completely, partially or nonmuscularized. Groups analyzed by ANOVA for overall change with posttest analysis; n  10 animals.
**P  0.01; P  0.05, for complete muscularized group in drug-treated vs. day 14 hypoxic control. H: lungs were removed after experiment and sections (5
mm) cut. These were stained with -smooth muscle actin, and the vessels100 mm were analyzed for degree of muscularization. Five to 10 random fields (40)
were analyzed with 3 slides per animal. The vessels were categorized as muscularized or nonmuscularized, and the percentage of muscularized vessels was
calculated. Groups analyzed by ANOVA for overall change with posttest analysis; n 10 animals. ****P 0.0001; P 0.05 for drug-treated vs. day 14 MCT
control.
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novel agent with greater specificity for this isoform than
SB203580 (3).
Chronic hypoxic animals. We adopted a reversal strategy
whereby the animals were treated daily intraperitoneal injec-
tions of PH-797804 after 2 wk of chronic hypoxia. Similar to
the study with SB203580 we found a significant reduction in
the RVSP in the drug-treated animals after 2 wk of treatment
(Fig. 5A) accompanied by a marked reduction in the degree of
RVH compared with both 14- and 28-day time points (Fig. 5B),
with no change in hematocrit (data not shown). The pulmonary
vascular muscularization was reversed in the drug-treated
group compared with the 28-day animal untreated group (Fig.
5, C and D). Systemic BP remained unchanged. (data not
shown).
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MCT animals. PH-797804 was shown to improve the RVSP in
animals with established MCT-induced pulmonary hypertension
(Fig. 5E). There was an improvement in the RVH in the drug-
treated animals compared with the 14- and 28-day time points
(Fig. 5F). Attenuation of progression in the degree of muscular-
ization of the vessels in the drug-treated animals compared with
the day 28 untreated animals was identified, and there was a
reduction of muscularization in the treated group compared with
the day 14 untreated animals, as shown Fig. 5G. Furthermore
when the percentage of muscularized vessels was calculated and
expressed as percentage of the total number of vessels, this
demonstrated that there was a significant reduction in the overall
degree of muscularization compared with day 14 MCT (Fig. 5H).
Again the systemic BP was unaltered (data not shown).
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p38 MAPK Inhibition Reduced Hypoxia-Induced Release of
IL-6 from Pulmonary Artery Fibroblasts
Exposure of RPAF to hypoxia for up to 48 h led to upregu-
lation of IL-6 and release of IL-6 from the cells. Secreted levels
of IL-6 were significantly increased at 48 h of exposure.
Treatment of cells with SB203580 prevented the release of the
IL-6 from hypoxia-exposed fibroblasts (Fig. 6, A and B). This
was time dependent with peak mRNA effect observed at 12 h
after hypoxic exposure (Fig. 6C). This was reduced in the
presence of p38 inhibition (data not shown). Further studies
showed that pulmonary artery fibroblasts proliferate in re-
sponse to IL-6, which was not significantly increased in the
presence of the soluble IL-6R- subunit (testing transactivation
of the IL-6 pathway) but was more pronounced under hypoxic
conditions (Fig. 6D). In PASMCs, the addition of IL-6 also
proved to be a strong mitogen (Fig. 6E) and incubation with
anti-IL-6 blocked the PASMC proliferation (Fig. 6F). In addi-
tion, the proliferation via IL-6 seemed to be mediated by the
classical STAT-3 pathway with increased phosphorylation in a
time-dependent manner as shown (Fig. 6, G and H).
In vivo p38 MAPK Inhibition Reduces Production of Tissue
and Circulating IL-6 and Reverses Proproliferative
Phenotype of Fibroblast
In the prevention study of the chronic hypoxic-associated
pulmonary hypertension we found a reduction in IL-6 levels in
the lungs of SB203580 drug-treated animals compared with
vehicle-treated hypoxic controls (Fig. 7A). Similarly, in the
reversal study with SB203580, IL-6 levels were reduced in the
lung and the amount of phospho-STAT3 signaling was reduced
(Fig. 7, B–D).
The same findings were observed in the MCT animals with
reduced IL-6 levels in the SB203580 drug-treated animals (Fig.
7E). In the reversal studies using PH-797804, serum levels
were examined and a significant reduction in serum IL-6 level
was seen in the chronic hypoxic and MCT reversal study (Fig.
7, F and G). Other cells such as neutrophils can act as IL-6
reservoirs, and it is likely that the fibroblast is not the only
source of IL-6. However, initial experiments have shown no
increase in neutrophil activity in our models (data not shown).
Of interest is that the fibroblasts isolated from the pulmonary
artery of the experimental models following treatment with p38
inhibition, no longer demonstrated the proproliferative pheno-
type previously observed (Fig. 7H). This suggests that in the
experimental pulmonary hypertension fibroblast blockage of
the p38 MAPK pathway can restore normal phenotype to the
cell in vivo. This may be one of the factors leading to the
reversal of PVremod in the drug-treated animals.
Increased Expression of phospho-p38 MAPK and p38
MAPK in Vessels from Human IPAH Patients
Immunohistochemical staining of sections from the lungs of
patients with IPAH who had undergone transplantation showed
increased phospho-p38 MAPK expression compared with con-
trol lungs (Fig. 8A). This is shown in all layers of the vascular
wall (Fig. 8B). There was increased staining for p38 MAPK,
which was mainly in a nuclear distribution in the control
vessels but involved both nuclear and cytoplasmic staining in
the IPAH patients (Fig. 8, C and D). This was again demon-
strated in all the layers of the vascular wall (Fig. 8E). With the
use of an intensity scoring technique, there was higher expres-
sion demonstrated for p38 MAPK in the vessels of patients
with IPAH compared with controls (Fig. 8F) (1).
In the identified plexiform lesion, there was strong cellular
staining for p38 MAPK in cells around the vascular channels
in both cytosol and nucleus (Fig. 8G).
DISCUSSION
This study advances our understanding of the potential role
that p38 MAPK plays in the biology of pulmonary vascular
remodeling. It demonstrates that p38 MAPK is implicated in
the pathogenesis of pulmonary hypertension and administra-
tion of selective p38 MAPK inhibitors in vivo demonstrated
that the pulmonary hypertensive phenotype cannot only be
prevented, but reversed, with improvements in PVremod, act-
ing through inhibition of key inflammatory mediators such as
IL-6. Although p38 MAPK has been implicated previously in
cytokine biosynthesis and to have a role in MCT-induced
pulmonary hypertension, this study is the first to show that the
-isoform is specifically implicated and inhibition can lower
IL-6 levels and reverse disease. This suggests there may be a
novel link between p38 MAPK signaling and inflammation in
the development of pulmonary vascular remodeling.
Fig. 6. p38 MAPK inhibition reduces interleukin (IL)-6 generation and signaling as a potential mechanism for beneficial effects in PH. A and B: supernatant
from normoxic and hypoxic PAF  SB203580 was analyzed using a quantitative ELISA to determine actual amounts released. Cells were growth arrested in
serum free media for 24 h before hypoxic exposure. The values are mean  SE values from triplicate wells for each sample and experiment repeated 3 times
using cells from 3 animals. *P  0.05 **P  0.005. C: PAF were exposed to hypoxia and then RNA isolated after 48 h. The RNA was reverse transcribed into
cDNA and then analyzed using quantitative (q)RT-PCR. The mRNA increased and peaked at 12 h of hypoxia. Values represent ratio of increase of IL-6 gene
mRNA relative to the housekeeping gene of 
-actin and calculated using comparative Ct method. Values are representative of triplicate samples from 3
experiments using 3 different animals. D: PAF were exposed to hypoxia in the presence of SB203580 and then RNA isolated after 48 h. The RNA was reverse
transcribed into cDNA and then analyzed using qRT-PCR. The mRNA increased and peaked at 12 h of hypoxia. Values represent ratio of increase of IL-6 gene
mRNA relative to the housekeeping gene of 
-actin and calculated using comparative Ct method. Values are representative of triplicate samples from 3
experiments using 3 different animals. **P 0.01; ***P 0.01, for C and D. E: PAF were isolated and incubated with IL-6 (100 ng/ml) soluble IL-6 receptor
(sIL-6) and then using DNA synthesis as a marker of cell proliferation, the response was observed. Data are mean values SE and are representative of duplicate
experiments performed on cells from 3 different animals. *P  0.05; **P  0.005; ***P  0.0001. F: PASMCs were exposed to IL-6 (100 ng/ml)  soluble
IL-6 receptor (sIL-r) and then using DNA synthesis as a marker of cell proliferation, the response was observed. Data are means  and are representative of
duplicate experiments performed on cells from 3 different animals. ****P  0.0001. G: PASMCs were growth arrested for 24 h and then incubated with serum
free media, IL-6 or IL-6 and anti-IL-6 antibody. Thymidine assay was used to quantify DNA synthesis, a measure of cell proliferation. Results are plotted as
counts per million. Values are means  SE and represent mean of 3 experiments on cells from same animal. A total of 3 different animals were used. **P 
0.01. H and I: PASMCs were stimulated with 100 ng/ml IL-6 () or without () and the protein harvested at baseline, 15 min, 30 min, 1 h, and 4 h. The cell
lysates were immunoblotted for phosphorylated STAT3 and total STAT3. Experiment was repeated 3 times; blots above are representative of those experiments.
H shows densitometry from repeat blots. ***P  0.005; ****P  0.001, for I.
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The fibroblast is an important cell in the pathobiology of
pulmonary vascular remodeling and dysregulation of the p38
MAPK pathway in the fibroblast can result in aberrant prolif-
eration. We have previously shown, along with others, that the
fibroblast undergoes a proproliferative phenotypic switch when
exposed to chronic hypoxia and that p38 MAPK is critically
involved. Here we have shown a similar proproliferative trans-
formation with the fibroblasts isolated from MCT animals,
again mediated through p38 MAPK. Conditioned media iso-
lated from the hypoxic fibroblast can stimulate smooth muscle
cell proliferation and using cytokine arrays, IL-6 was identified
as a potential key mediator that was being released by the
fibroblast under hypoxic conditions. IL-6 release was blocked
by the p38 MAPK inhibitor SB203580 in fibroblasts, implicat-
ing p38 MAPK in both proliferation and cytokine biosynthesis
in this cell. Similar findings were obtained from conditioned
media isolated from fibroblasts derived from experimental
animal models of pulmonary hypertension. Therefore, our in
vitro fibroblast studies showed that under acute hypoxic con-
ditions there was increased IL-6 production and that IL-6 can,
through a STAT-3 pathway, stimulate proliferation of the
smooth muscle cell and fibroblast.
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Increased activity of p38 MAPK in both chronic hypoxic
and MCT lung homogenates is in concordance with a previous
study showing increased activity of the entire MAPK signaling
group in large pulmonary arteries of chronically hypoxic rats
(5). However, that study did not specifically demonstrate
whether p38 MAPK activity itself was increased or address
-isoform expression. Here, we have shown evidence that p38
MAPK and the -isoform are upregulated in the pulmonary
vessels of two different in vivo animal models of pulmonary
hypertension and has been implicated as a proproliferative and
proinflammatory pathway in the pulmonary artery fibroblast.
Using the p38 MAPK inhibitor SB203580 we showed that
blocking p38 MAPK could prevent the development of pul-
monary hypertension as previously described in a MCT study
that looked at prevention of the disease only (8). Although
prevention studies are critical in outlining early pathogenic
mechanisms, studies with established disease are more clini-
cally relevant. In this study after development of established
pulmonary hypertension in both hypoxic and MCT models,
daily administration of SB203580 reversed the RVSP and
RVH and also improved PVremod.
The novel and specific p38 MAPK inhibitor PH-797804
has been shown to be extremely effective in animal models of
rheumatoid arthritis with a 6.9-fold increase in specificity
relative to the p38 MAPK 
-isoform compared with existing
inhibitors (3). Furthermore, it has shown tolerability, safety,
and efficacy in a clinical trial of patients with chronic obstruc-
tive pulmonary disease (9). This allowed us to use a drug that
has the potential for future development in the treatment of
patients with pulmonary hypertension. In addition the targeting
of the more specific isoform differentiates the systemic and
pulmonary circulation. The p38 MAPK pathway seems to be
preferentially upregulated in the pulmonary circulation in pul-
monary hypertension and hence provides a rationale for tar-
geting of this pathway. There is support from a study looking
at bleomycin-induced pulmonary fibrosis in rats. This showed
that inhibition of p38 MAPK can prevent the development of
RVH, although this was a prevention study in an animal model
not representative of true pulmonary arterial disease (18).
Although no animal model fully recapitulates disease, the
models employed in this study are established and recognized
models of pulmonary arterial hypertension.
Our data with PH-797804, performed in reversal in vivo
studies, produced similar findings to SB203580 with a reduc-
tion in the RVSP and RVH and significant attenuation of
PVremod in the chronic hypoxic model. There was improve-
ment in the RVSP in the drug-treated MCT group and a
significant reversal and attenuation in progression of RVH. The
reason that there was a greater observed reduction in the
remodeling in the SB203580-treated animals may reflect that
the dose used for PH-797804 was not optimal for this com-
pound or that the length of administration was not long enough.
The dose and length of administration for SB203580 in other
animal models have been clearly identified. However, one of
the novel aspects of this study is that using a clinically
available, specific p38 MAPK inhibitor leads to reversal of
pulmonary vascular remodeling in two well-established animal
models of pulmonary hypertension.
Cytokines and inflammatory responses have been recog-
nized as a driver for PVremod and p38 MAPK has been
implicated in inflammatory processes. IL-6 is a known mitogen
for vascular smooth muscle cells, and previous transgenic
murine studies have implicated IL-6 in the etiology of pulmo-
nary hypertension (2, 10, 16). Moreover, a recent study has
identified the upregulation and increased release of IL-6 from
pulmonary artery fibroblasts derived from chronic hypoxic
calves (7). In addition, serum levels of IL-6 correlate with the
prognostic outcome in patients with IPAH (15).
Our in vitro studies showed the fibroblast to be a source of
IL-6, and in both prevention and reversal studies we found a
reduction in the concentration of IL-6 in the lungs and serum
of drug-treated animals. Although likely not to be the only
source of IL-6, the data presented here suggest the fibroblast
can be an important source of this proinflammatory cytokine in
the pulmonary vasculature. Studies on human umbilical vas-
cular endothelial cells and alveolar macrophages have also
shown that p38 MAPK inhibition can reduce IL-6 release (6,
18). However, our study has shown that inhibition of p38
MAPK resulted in a reversal of the proproliferative pheno-
type in the fibroblast isolated from in vivo-treated animals,
suggesting that in experimental models inhibition can alter
the underlying pathological process in the pulmonary vas-
culature. This study has shown modest reductions in lung
IL-6 and serum levels of IL-6. Although not conclusive in
Fig. 7. p38 MAPK inhibition in vivo leads to reduced IL-6 in experimental models of PH. A: lungs were isolated from CH animals in the prevention study with
SB203580 and homogenized. The protein concentration was normalized by protein concentration as per BCA method. ELISA was used to analyze for IL-6 levels
in the lung tissue. Data shown are means  SE from triplicate samples from 4/5 animals in each group. B: lungs were isolated from normal and CH animals
after treatment in reversal strategy with SB203580 and homogenized. The protein concentration was normalized by protein concentration as per BCA method.
ELISA was used to analyze for IL-6 levels in the lung tissue. Drug-treated and normal control animals are at 28 days. Data shown are means SE from triplicate
samples from 4/5 animals in each group. *P 0.05 **P 0.01. C and D: lungs from CH 28-day controls and SB203580-treated hypoxic animals were harvested
and homogenized with a cocktail of phosphatase and kinase inhibitors. The protein concentration was quantified using BCA method. Equal concentrations were
then loaded on a gel and blotted for phospho-STAT3 and total STAT3. Immunoblot shown is best representative of 3 experiments using lungs from 3 different
animals with each condition. Densitometry is shown of other blots. **P 0.001. E: lungs were isolated from MCT and normal control animals and homogenized.
Inhibitor used was SB203580. The protein concentration was normalized by protein concentration as per BCA method. ELISA was used to analyze for IL-6 levels
in the lung tissue. Data shown are means  SE from triplicate samples from 4/5 animals in each group. *P  0.05; ns is not significant by ANOVA. F:
PH-797804 reduces serum IL-6 in reversal of CH-induced PH. Serum was collected from animals at the time of cardiac puncture and stored at 80°C until
analysis could be performed. ELISA for IL-6 was performed on serum samples. Values shown are means  SE. Samples were analyzed in duplicate and total
animal number n  11. ***P  0.005. G: PH-797804 reduces serum IL-6 in reversal of MCT-induced PH. Serum was collected from animals at the time of
cardiac puncture and stored at 80°C until analysis could be performed. ELISA for IL-6 was performed on serum samples. Values shown are means  SE.
Samples were analyzed in duplicate and total animal number n  12. *P  0.01; ***P  0.005. H: fibroblasts undergo phenotypic switch back to normal after
p38 MAPK inhibition. PAF were cultured from pulmonary arteries derived from normal, experimental models of PH (CH and MCT) and from animals after
treatment with p38 MAPK inhibition PH-787904 for 2 wk. Cells were challenged with or without serum to assess proliferation; n  3–4 per group. Experiment
repeated 3 times. **P  0.01, ***P  0.001.
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these studies, it does raise the interesting possibility that p38
MAPK inhibition reduces local and serum IL-6 levels and
that this may underplay a key role in the reversal of
pathological remodeling.
Of major interest was our finding of increased activity of
phosphorylated p38 MAPK and expression of p38 MAPK in
the vessels of explanted lungs from patients with IPAH. To our
knowledge this is the first time this has been shown in pulmo-
nary arterial hypertension. This was seen in both large and
small vessels with increased nuclear and cytosolic distribution,
involving endothelial, smooth muscle, and fibroblast cells,
including the plexiform lesion, which is pathognomonic of
pulmonary vasculopathy. The findings of p38 activation in all
layers of the vasculature would suggest that it is unlikely that
inhibition of p38 MAPK in the fibroblast alone is producing
reversal of the experimental pulmonary hypertension. Indeed
our previous work demonstrated that the endothelium in hy-
poxic pulmonary hypertension is associated with impaired
relaxation and reduced nitric oxide production, which could be
reversed by inhibition of p38 MAPK (19). However, our data
clearly suggest that p38 MAPK is an important pathway
throughout the pulmonary vasculature but that the activation of
this pathway is critical in the fibroblast, a key cell in the
process of PVremod.
In summary, the findings presented here suggest a critical
role for p38 MAPK and the -isoform in the development and
progression of pulmonary hypertension. The fact that increased
p38 MAPK activity and expression are observed in both
hypoxia and MCT animal models and in human disease sug-
gests a common role in the etiology of many forms of pulmo-
nary hypertension. Furthermore, p38 MAPK signaling through
IL-6 provides a novel link between vascular remodeling and
inflammation. This provides us with the exciting prospect of a
new anti-inflammatory target for the treatment of pulmonary
Fig. 8. Phospho-p38 MAPK and p38
MAPK expression in explanted lungs from
patients with idiopathic pulmonary arterial
hypertension (IPAH). A: sections of 5 mm
were taken. Then, normal control lung and
IPAH lung are stained for phospho-p38
MAPK at dilution of 1:300. The isotype on
IPAH lung is also shown. This dilution was
optimally assessed for. Objective:20. Bar
150 mm. B: high-power microscopy shows
that there is strong staining for phospho-p38
MAPK in the intima, media, and the adven-
titia (arrows). Objective lens: 20 and 40.
Bar  50 mm. C: sections of control lung
(A) and IPAH lung (B) were stained for p38
MAPK at dilution of 1:300. Objective lens 
20. Bar  150 mm. D: staining for p38
MAPKa showed increased cytosolic staining
in the IPAH lung (right) compared with
control lung (left). E: high-power view
(40) of staining with isotype and p38
MAPK in a vessel in IPAH lung. This
shows staining throughout the vessel layers
but especially in adventitia and fibroblast
cells (arrow). Bar  50 mm. F: low-power
view of a plexiform lesion. Staining for p38
MAPK using 1:300 dilution. Objective
lens  20. Bar  150 mm. G: histological
scoring shows increased p38 MAPK stain-
ing throughout the vascular wall. With the
use of a well-validated histological scoring
system (Allred), the vascular wall cells were
scored for intensity of staining. The intensity
multiplied by the number of vessels with that
intensity determines the values. Values
shown are from 5 random high-power fields
from 2 slides. ****P  0.0001 by ANOVA.
**P 0.001 for individual IPAH vs. control
columns.
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hypertension which improves the underlying remodeling pro-
cess.
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